For research and educational purposes only. Not intended for human consumption.
Tesamorelin
Extensively Studied- •March 2025 Egrifta WR FDA approval
- •15-18% VAT reduction confirmed
- •37% liver fat reduction in NAFLD
GHRH Analog | Visceral Fat Reduction
Overview
What is Tesamorelin?
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog for treating HIV-associated lipodystrophy. Phase 3 trials confirm 15-18% visceral adipose tissue (VAT) reduction at 2mg daily dose, sustained up to 12 months. March 2025 FDA approval of Egrifta WR (concentrated formulation) enhances dosing convenience. Also shows 37% liver fat reduction in NAFLD patients. Banned by WADA
Key Benefits
FDA-approved (Egrifta, Egrifta WR) with 15-18% VAT reduction in pivotal trials. 37% hepatic fat reduction in HIV-NAFLD. March 2025 formulation update improves dosing. Selective visceral fat targeting preserves subcutaneous fat. Mechanisms favor visceral/liver fat loss over subcutaneous fat while preserving muscle mass.
Mechanism of Action
Stimulates endogenous GH release via GHRH receptor binding, favoring visceral/liver fat mobilization through lipolysis. Unlike caloric restriction, preserves muscle mass. Unique selectivity for visceral fat reduction with sustained effects requiring continuous treatment.
Molecular Information
Pharmacokinetics
Research Indications
HIV-Associated Lipodystrophy
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.
Selective Visceral Fat Targeting
Unique mechanism spares subcutaneous fat while reducing harmful visceral adiposity.
Sustained Fat Loss
Maintained weight loss with continuous treatment over 52+ weeks.
Research Protocols
Disclaimer: Tesamorelin is FDA-approved (Egrifta). These protocols reflect clinical guidelines. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV Lipodystrophy (FDA Approved) | 1.4mg daily | Once daily | Subcutaneous (abdomen) |
| Visceral Fat Reduction | 2mg daily | Once daily | Subcutaneous (rotate sites) |
| Anti-aging/Body Composition | 1-2mg daily | 5-7 days/week | Subcutaneous (evening) |
| NAFLD Treatment | 2mg daily | Once daily | Subcutaneous for 12 months |
Timing: Evening injection aligns with natural growth hormone circadian rhythm. Take after dinner but before bedtime for optimal efficacy.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigerator and allow to reach room temperature
Egrifta SV: Add 0.5 mL sterile water to 2 mg vial
Egrifta WR: Add 1.3 mL bacteriostatic water to 11.6 mg vial
Gently swirl to dissolve - do not shake vigorously
Solution should be clear and colorless
Withdraw appropriate dose (typically 0.35 mL for 1.4 mg)
Inject subcutaneously in abdomen, rotating sites
SV: Use immediately. WR: Store at room temp for up to 7 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
FDA-Approved Formulations
Egrifta SV or WR from licensed pharmacy with proper documentation.
White Crystalline Powder
Lyophilized powder should be white, uniform, and cake-like.
Clear Reconstituted Solution
After mixing, solution should be clear and colorless.
Proper Packaging Integrity
Sealed vials with intact rubber stoppers and aluminum seals.
Discolored or Cloudy Solution
Any color or cloudiness indicates degradation.
Visible Particles
Particles indicate protein aggregation or contamination.
What to Expect
- •Week 1-2: IGF-1 levels begin to rise, possible mild water retention
- •Week 4-6: Early metabolic changes, slight improvements in energy and sleep
- •Week 8-12: Visible visceral fat reduction begins, waist circumference decreases
- •Week 12-26: Peak effects achieved with significant body composition improvements
Side Effects & Safety
Side Effects
- •Monitor blood glucose regularly - 3.3-fold increased diabetes risk documented
- •IGF-1 levels should be checked monthly - 47% exceed normal range at 26 weeks
- •Contraindicated in active malignancy or pituitary disorders
- •Common side effects include injection site reactions (17%) and joint pain (13%)
When to Stop
- •Significant blood glucose changes
- •Active cancer diagnosis
- •Pituitary problems
- •Severe injection site reactions
- •As directed by physician
References
5 StudiesPhase 3 LIPO-010/CTR-1011 Trials (2005-2010)
Human | 2mg daily | HIV lipodystrophy | 15-18% VAT reduction sustained to 12 months
Pivotal trials confirming visceral adipose tissue reduction outperforming placebo, leading to FDA approval. Effects maintained up to 12 months with continued treatment.
Egrifta WR FDA Approval (March 2025)
Regulatory | Concentrated formulation | Enhanced dosing convenience
March 2025 FDA approval of concentrated F8 formulation (Egrifta WR) improves dosing convenience without altering core efficacy or safety profile.
NAFLD Treatment Trial - Stanley et al (2020)
Human | HIV-NAFLD patients | 12 months | 37% hepatic fat reduction + reduced inflammation/fibrosis
Randomized trial showed 37% hepatic fat reduction plus lowered inflammation and fibrosis markers in HIV-associated NAFLD.
View StudyQuick Start Guide
Research Disclaimer
Tesamorelin is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Tesamorelin must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Tesamorelin for any purpose. Consult qualified professionals for any research applications.